CDMO BioDuro acquires Molecular Response

Based in San Diego-CA, Molecular Response’s platform includes a collection of viable tumor specimens, including tumor, immune, and stromal cells for in vitro​ and in vivo​ studies.

TJ Deng, general manager for BioDuro Discovery, said the company is committed to growing into a “complete chemistry and biology provider​,” adding, “unique platforms in oncology are a critical centerpiece of that strategy​."

According to the contract research and development organization (CDMO), the platform supports various drug discovery oncology and immune-oncology studies, including immunophenotyping screens and xenograft pharmacology studies.

"The Molecular Response acquisition immediately strengthens our capability and provides our clients a continuous set of capability, enabling our customers to start with our chemistry services through preclinical and translational oncology studies, all the way to IND,"​ he said in a press release.

Following the acquisition, terms of which were not disclosed, Molecular Response will operate as a wholly-owned subsidiary of BioDuro and will continue selling its biospecimens to strategic partners.

Molecular Response CEO, Thomas Broudy, PhD will become Executive Vice President, Translational Sciences and Strategy.